Recent Methods in Antimalarial Susceptibility Testing

Co, Ewenighi; Johnson, Sydney; Murthy, T.; Talwar, Mayank; Hickman, Mark; Johnson, Jacob

doi:10.2174/1871521411009030148

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They argued that by using panels of mAbs against pLDH, a P. knowlesi -specific RDT can be developed. There is currently no rapid immunological test for the detection of P. knowlesi and, therefore, more sophisticated and expensive tools such as flow cytometry, nested PCR and real-time PCR need to be employed (Co et al ., 2010; Singh & Daneshvar, 2010).…”

Section: Malaria Diagnosis Using Rapid Diagnostic Testsmentioning

confidence: 99%

Malaria rapid diagnostic tests: challenges and prospects

Mouatcho

Goldring

2013

Journal of Medical Microbiology

234

231

View full text Add to dashboard Cite

In the last decade, there has been an upsurge of interest in developing malaria rapid diagnostic test (RDT) kits for the detection of Plasmodium species. Three antigens-Plasmodium falciparum histidine-rich protein 2 (PfHRP2), plasmodial aldolase and plasmodial lactate dehydrogenase (pLDH)-are currently used for RDTs. Tests targeting HRP2 contribute to more than 90 % of the malaria RDTs in current use. However, the specificities, sensitivities, numbers of false positives, numbers of false negatives and temperature tolerances of these tests vary considerably, illustrating the difficulties and challenges facing current RDTs. This paper describes recent developments in malaria RDTs, reviewing RDTs detecting PfHRP2, pLDH and plasmodial aldolase. The difficulties associated with RDTs, such as genetic variability in the Pfhrp2 gene and the persistence of antigens in the bloodstream following the elimination of parasites, are discussed. The prospect of overcoming the problems associated with current RDTs with a new generation of alternative malaria antigen targets is also described.

show abstract

Section: Malaria Diagnosis Using Rapid Diagnostic Testsmentioning

confidence: 99%

Malaria rapid diagnostic tests: challenges and prospects

Mouatcho

Goldring

2013

Journal of Medical Microbiology

234

231

View full text Add to dashboard Cite

show abstract

“…Majority of these deaths occur in sub Saharan Africa where the disease is highly endemic and most difficult to manage. Initiatives by the World Health Organization (WHO), the Gates Foundation, the Global Fund and the World Bank for reduction and eradication of this disease are achieving great success (Co et al 2010). Initiatives by the World Health Organization (WHO), the Gates Foundation, the Global Fund and the World Bank for reduction and eradication of this disease are achieving great success (Co et al 2010).…”

Section: Introductionmentioning

confidence: 99%

“…Efforts to control this disease are hampered by drug resistance in parasites, insecticide resistance in mosquitoes, and lack of an effective vaccine (Maciel et al 2008). Initiatives by the World Health Organization (WHO), the Gates Foundation, the Global Fund and the World Bank for reduction and eradication of this disease are achieving great success (Co et al 2010). This is attributable to a number of actions, most significant of which is the recommendation of artemisinin-based combination therapy (ACT) as first line treatment of uncomplicated malaria by the World Health Organization (WHO, 2010).…”

Section: Introductionmentioning

confidence: 99%

Amodiaquine–Ciprofloxacin: a potential combination therapy against drug resistant malaria

et al. 2015

View full text Add to dashboard Cite

Emergence of malaria parasites resistant to artemisinin necessitates the need for development of new antimalarial therapies. Ciprofloxacin (CFX) a second generation quinolone antibiotic possesses some antimalarial activities. We investigated the in vivo antimalarial activities of CFX in combination with amodiaquine in mice infected with chloroquine-resistant Plasmodium berghei ANKA. Animals were treated orally with 80 or 160 mg kg-1 body weight of CFX alone given twice daily or in combination with amodiaquine (AQ) 10 mg kg-1 body weight. Parasitological activity and survival of the animals were assessed over 21 days. Peak parasitaemia in the untreated control group was 72.51%. Treatment with AQ alone resulted in clearance of parasitaemia by day 4 while treatment with CFX 80 and 160 mg kg-1 alone suppressed parasitaemia by 13.94-54.64% and 35.6-92.7%, respectively. However, the combination of CFX with AQ significantly enhanced response of infection in the animals to treatment (P < 0.05) resulting in complete resolution of parasitaemia throughout follow up period with CFX 160 mg kg-1, delayed recrudescence time with CFX 80 mg kg-1 and significant increase in survival rate of the animals. The results demonstrate beneficial interaction between AQ and CFX which may provide a clinically relevant antimalarial/antibiotic therapeutic option in the management of malaria.

show abstract

Cell based assays for anti-Plasmodium activity evaluation

Mokgethi-Morule

N’Da

2016

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Recent Methods in Antimalarial Susceptibility Testing

Cited by 3 publications

References 0 publications

Malaria rapid diagnostic tests: challenges and prospects

Malaria rapid diagnostic tests: challenges and prospects

Amodiaquine–Ciprofloxacin: a potential combination therapy against drug resistant malaria

Cell based assays for anti-Plasmodium activity evaluation

Contact Info

Product

Resources

About